Search results
Results From The WOW.Com Content Network
Alcon Inc. ( German: Alcon AG) is a Swiss-American pharmaceutical and medical device company specializing in eye care products. It has a paper headquarters in Geneva, Switzerland but its operational headquarters are in Fort Worth, Texas, United States, where it employs about 4,500 people. [2]
The total cost to Novartis for the 77% stake in Alcon was $38.7 billion ($168 per share). In the deal's first phase, Novartis acquired a 25% stake in Alcon from Nestlé for $10.4 billion in July 2008.
Novartis. / 47.5744252; 7.5764914. Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health ( list...) Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical ...
Organon & Co. Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. [4] Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but gets ...
Alcon relocated its headquarters to Geneva in 2018, citing an opportunity to “increase Alcon’s global scale and reach to better serve customers.” The company employs a total of 25,000 people.
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
Between the company's shrinking business in 2023 and the current high dividend yield, skeptical investors may balk at buying shares, fearing that the company's financial health is in jeopardy.
In-dividend date – the last day, which is one trading day before the ex-dividend date, where shares are said to be cum dividend ('with [including] dividend'). That is, existing shareholders and anyone who buys the shares on this day will receive the dividend, and any shareholders who have sold the shares lose their right to the dividend.